Pandion Therapeutics, Inc. Company Profile

16:51 EDT 24th June 2018 | BioPortfolio

Pandion Therapeutics is a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation at the site of disease for durable, tissue-specific treatment, while avoiding the systemic immunosuppression of conventional medicines. The company’s proprietary technology platform enables the design of bispecific antibodies with targeting fragments that bind to specific tissues at the local site of inflammatory disease, coupled with effector molecules that modulate immune activity to restore immune homeostasis. With its robust antibody platform, Pandion is developing a pipeline for autoimmune and inflammatory diseases and transplantation, with an initial focus on diseases of the gut, liver, kidney, pancreas, and skin.

News Articles [797 Associated News Articles listed on BioPortfolio]

BRIEF—Pandion Therapeutics raises $58 million and appoints new chief executive

East Coast, USA-based Pandion Therapeutics has raised $58 million in a series A funding round, co-led…

Funding round raises $58M for Pandion Therapeutics

A Series A funding round brought in $58 million for Pandion Therapeutics.  -More- 

Pandion raises $58M for its autoimmune platform inspired by the tumor microenvironment

Oncology has long been borrowing lessons from immunology. It may now be time to pay it back. Pandion Therapeutics is tapping into some immune evasion tools observed in cancer to better treat autoimmun...

Pandion raises $58mm in Series A round

Pandion Therapeutics Inc. (bispecific antibodies for inflammatory and autoimmune diseases) raised $58mm through its Series A round. Seed investor Polaris Partners co-led the round, alongside Versant V...

Pandion Raises $58M to Bring Cancer-Fighting Tactics to Immune Disorders

Many drugs for inflammatory and autoimmune disorders work by suppressing the immune system, an approach that puts patients at risk of infection among other side effects. Pandion Therapeutics is develo...

Cambridge's Pandion Therapeutics Emerges With $58M and Two Superstar Execs as CEO, CSO

The cash will be used to advance its initial drug programs for autoimmune and inflammatory diseases toward the clinic.

Finance Watch: Pandion's $55m Series A Funds Localized Bispecifics For Autoimmune Diseases

Pandion, led by former Pfizer SVP Anthony Coyle, launched in 2017 to exploit immuno-oncology advances for autoimmune and inflammatory diseases;...   

Biotech raises $58 million in funding to advance drug programmes

Pandion Therapeutics, a biotechnology company, has raised $58 million at the completion of its Series A financing round, which will be used to advance its initial drug programmes for autoimmune and in...

PubMed Articles [433 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

Recent developments in intracellular protein delivery.

Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...

Alternative therapeutics for self-limiting infections-An indirect approach to the antibiotic resistance challenge.

Alternative therapeutics for infectious diseases is a top priority, but what infections should be the primary targets? At present there is a focus on therapies for severe infections, for which effecti...

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Eyes on New Product Development: Preclinical Research.

Clinical Trials [144 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1238 Associated Companies listed on BioPortfolio]

Pandion Therapeutics, Inc.

Pandion Therapeutics is a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation at the site of disease for durable, tissue...

Pandion Systems, Inc

Pandion Systems, Inc. derives its name from the Osprey, Pandion haliaetus. The Osprey is a species found throughout the world in the natural as well as the human environment. It is a symbol of balance...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

More Information about "Pandion Therapeutics, Inc." on BioPortfolio

We have published hundreds of Pandion Therapeutics, Inc. news stories on BioPortfolio along with dozens of Pandion Therapeutics, Inc. Clinical Trials and PubMed Articles about Pandion Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Pandion Therapeutics, Inc. Companies in our database. You can also find out about relevant Pandion Therapeutics, Inc. Drugs and Medications on this site too.

Quick Search


Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Autoimmune Disorders
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...

Corporate Database Quicklinks

Searches Linking to this Company Record